Precision Medicine is going to be at the forefront of the next era of clinical treatment; and what is at the forefront of Precision Medicine?
Whether you are using it for drug development or diagnosis, there are still hurdles to overcome to effectively implement the next era of genomic medicine.
Join us at Genomics Live 2020 where we will be bringing together leaders from Pharma, Healthcare and Academia to share insights and improve efficiencies that will benefit patients worldwide.
Digital Pathology & Tissue Diagnostics
An integral step in the diagnostic process is pathological analysis. The digitalisation of this is rapidly advancing the diagnostic space, offering a more accurate and timely response to patients and aid in research.This track will showcase the latest in the development of Digital Pathology technologies, showcase how this can be of benefit to the key research that is driving industry and streamline hospital diagnostics.
Novel Technologies & Clinical Biomarkers
The success of patient-centric precision medicine relies on a solid predictive biomarker foundation. While drug developers fight for market share for similar drug targets, healthcare providers are looking for robust clinical benefit to patients. Luckily, advancements in the next generation of biomarkers is rapid and novel biomarker and genomic technologies are paving the way for this. This track brings together leaders to showcase the latest case studies in the search for novel biomarkers, opportunities for growth and overcoming the challenges for biomarkers as therapeutic targets.
Immuno-oncology & Companion Diagnostics
Progress in the immuno-oncology space is rapidly advancing cancer treatment, but there are still challenges in patient stratification and monitoring. Companion Diagnostics can offer insight into immunotherapy efficacy, safety and can expedite immunotherapies to the market. This track is designed to discuss the latest development of robust assays, overcoming commercialisation issues and showcase latest patient case studies.
Multi-omics & Precision Medicine
Precision Medicine is not based purely on Genomics, now, we are focusing on more drug targets, namely “multi-omics”, or “X-Omics”.
Using a combination of omics offers a more comprehensive understanding of the disease and targets.This track offers a unique opportunity to highlight the use of multi-omics and personalised sequencing to improve patient care, and how this can be implemented routinely.